Largest CIDP Trial Offers Promising Results for Drug Combo

Nearly 70% of patients showed improvement after treatment with efgartigimod plus rHuPH20 in phase 2 of the largest randomized controlled trial for CIDP to date.

Related Keywords

United States ,Denver ,Colorado ,American ,Jeffreya Allen ,Brettm Morrison , ,University Of Minnesota ,American Academy Of Neurology ,Johns Hopkins School Of Medicine ,Morrison ,American Academy ,Primary Endpoint ,Johns Hopkins School ,Chronic Inflammatory Demyelinating Polyradiculoneuropathy ,Chronic Inflammatory Demyelinating Polyneuropathy ,Idp ,Demyelination ,Emyelinating ,Eigg ,Mmunoglobulin G ,Corticosteroid ,Riga ,Immunoglobulin A ,Intravenous Immunoglobulin ,Disability ,Adverse Effects ,Side Effects ,Autoimmune Disease ,Intravenous ,V Intravenous ,Intravenous Route ,Minnesota ,Neuropathy ,Plasmapheresis ,Steroids ,Headache ,